amyotrophic lateral sclerosis news - Search News

BioSpace · 36m

Denali Suffers Another ALS Fail With Phase II/III Flop

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.

Reuters on MSN · 14h

Denali Therapeutics' ALS drug fails in mid-to-late stage trial

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.

Business Insider · 15h

Denali Therapeutics announces HEALEY ALS trial regimen misses endpoints

Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B

MarketWatch · 16h

Denali Therapeutics Says ALS Trial Didn't Meet Endpoints

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks. The biotechnology company said Monday that DNL343 didn't meet the primary endpoint of slowing disease progression as compared with a placebo.

FierceBiotech3h

Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Denali slides after ALS drug flunks clinical test

The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...

The Korea Times on MSN13h

Rapper Sean realizes 23-year dream with Korea's 1st ALS care facility

Sean, 52, rose to fame in the late 1990s as part of the rap duo Jinusean. After marrying actor Jung Hye-young in 2004, Sean ...

14h

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...

Synchron inks partnership with Team Gleason to raise BCI awareness

Synchron announced today that it expanded its partnership with Team Gleason to raise awareness for its brain-computer ...

2d

‘Rally 4 Nally’ hosts its 4th annual polar plunge, closes in on $400K in donations

The 4th annual Rally 4 Nally polar plunge took place on Saturday to raise awareness and donations for ALS. Rally 4 Nally, is ...

15h

Denali falls 9% to $18 afteramyotrophic lateral sclerosis study miss

EST Denali falls 9% to $18 afteramyotrophic lateral sclerosis study missDon't Miss Our New Year's Offers:Discover the latest stocks ...

Pharmaceutical Technology1d

Central Nervous System Disorders by Neuroplast for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.

4d

When your terminal illness makes you a TikTok star

After being diagnosed with ALS in 2022, Brooke Eby could have turned inward. Instead, she opened up — and found a fan base ...

ALS News Today4d

Muscle mass biomarker is associated with risk of developing ALS: Study

The creatinine-to-cystatin C ratio may indicate the risk of developing amyotrophic lateral sclerosis, a large-scale database ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results